Tumor suppressor p53 and its mutants in cancer metabolism

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 197-203

  Liu, Juan ^a   Zhang, Cen ^a   Hu, Wenwei ^a   Feng, Zhaohui ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Metabolism; Mutant p53; P53; Tumor suppressor

Indexed keywords

MUTANT PROTEIN; PROTEIN P53; FATTY ACID;

AUTOPHAGY; CANCER INHIBITION; CANCER METABOLISM; CARCINOGENESIS; CELL METABOLISM; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GAIN OF FUNCTION MUTATION; GENE MUTATION; GLYCOLYSIS; HOMEOSTASIS; HUMAN; LIPID METABOLISM; METABOLIC REGULATION; METABOLISM; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; P53 GENE; PENTOSE PHOSPHATE CYCLE; PROTEIN FUNCTION; SHORT SURVEY; APOPTOSIS; CELL AGING; CELL CYCLE CHECKPOINT; CELL TRANSFORMATION; ENERGY METABOLISM; GENETICS; MITOCHONDRION; MUTATION; NEOPLASM; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL AGING; CELL CYCLE CHECKPOINTS; CELL TRANSFORMATION, NEOPLASTIC; ENERGY METABOLISM; FATTY ACIDS; GLYCOLYSIS; HUMANS; MITOCHONDRIA; MUTATION; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE PATHWAY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84920189113     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.12.025     Document Type: Review

References (75)

1. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
2. Levine A.J., Oren M. The first 30years of p53: growing ever more complex. Nat. Rev. Cancer 2009, 9:749-758.
3. Olivier M., Hussain S.P., Caron de Fromentel C., Hainaut P., Harris C.C. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer 2004, IARC Scientific Publications, pp. 247-270.
4. Tommasino M., Accardi R., Caldeira S., Dong W., Malanchi I., Smet A., Zehbe I. The role of TP53 in cervical carcinogenesis. Hum. Mutat. 2003, 21:307-312.
5. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
6. Strong L.C. General keynote: hereditary cancer: lessons from Li-Fraumeni syndrome. Gynecol. Oncol. 2003, 88:S4-7. discussion S11-13.
7. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356:215-221.
8. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 1994, 4:1-7.
9. Harris S.L., Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908.
10. Brooks C.L., Gu W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell. 2006, 21:307-315.
11. Levine A.J., Hu W., Feng Z. The P53 pathway: what questions remain to be explored?. Cell Death Differ. 2006, 13:1027-1036.
12. Riley T., Sontag E., Chen P., Levine A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 2008, 9:402-412.
13. el-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1992, 1:45-49.
14. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
15. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
16. Vousden K.H., Ryan K.M. P53 and metabolism. Nat. Rev. Cancer 2009, 9:691-700.
17. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
18. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
19. Guppy M., Greiner E., Brand K. The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes. Eur. J. Biochem. 1993, 212:95-99.
20. Schwartzenberg-Bar-Yoseph F., Armoni M., Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004, 64:2627-2633.
21. Bensaad K., Tsuruta A., Selak M.A., Vidal M.N., Nakano K., Bartrons R., Gottlieb E., Vousden K.H. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120.
22. Kondoh H., Lleonart M.E., Gil J., Wang J., Degan P., Peters G., Martinez D., Carnero A., Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005, 65:177-185.
23. Contractor T., Harris C.R. P53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2. Cancer Res. 2012, 72:560-567.
24. Zhang C., Lin M., Wu R., Wang X., Yang B., Levine A.J., Hu W., Feng Z. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc. Natl. Acad. Sci. USA 2011, 108:16259-16264.
25. Boidot R., Vegran F., Meulle A., Le Breton A., Dessy C., Sonveaux P., Lizard-Nacol S., Feron O. Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Res. 2012, 72:939-948.
26. Feng Z., Levine A.J. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol. 2010, 20:427-434.
27. Kawauchi K., Araki K., Tobiume K., Tanaka N. P53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat. Cell Biol. 2008, 10:611-618.
28. Wamelink M.M., Struys E.A., Jakobs C. The biochemistry, metabolism and inherited defects of the pentose phosphate pathway: a review. J. Inherit. Metab. Dis. 2008, 31:703-717.
29. Harris I., McCracken S., Mak T.W. PKM2: a gatekeeper between growth and survival. Cell Res. 2012, 22:447-449.
30. Luo W., Semenza G.L. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol. Metab. 2012, 23:560-566.
31. Jiang P., Du W., Wang X., Mancuso A., Gao X., Wu M., Yang X. P53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol. 2011, 13:310-316.
32. Bourdon A., Minai L., Serre V., Jais J.P., Sarzi E., Aubert S., Chretien D., de Lonlay P., Paquis-Flucklinger V., Arakawa H., Nakamura Y., Munnich A., Rotig A. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat. Genet. 2007, 39:776-780.
33. Kulawiec M., Ayyasamy V., Singh K.K. P53 regulates mtDNA copy number and mitocheckpoint pathway. J. Carcinog. 2009, 8:8.
34. Lebedeva M.A., Eaton J.S., Shadel G.S. Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis. Biochim. Biophys. Acta 2009, 1787:328-334.
35. Achanta G., Sasaki R., Feng L., Carew J.S., Lu W., Pelicano H., Keating M.J., Huang P. Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J. 2005, 24:3482-3492.
36. Kitamura N., Nakamura Y., Miyamoto Y., Miyamoto T., Kabu K., Yoshida M., Futamura M., Ichinose S., Arakawa H. Mieap, a p53-inducible protein, controls mitochondrial quality by repairing or eliminating unhealthy mitochondria. PLoS One 2011, 6:e16060.
37. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., Hurley P.J., Bunz F., Hwang P.M. P53 regulates mitochondrial respiration. Science 2006, 312:1650-1653.
38. Stambolsky P., Weisz L., Shats I., Klein Y., Goldfinger N., Oren M., Rotter V. Regulation of AIF expression by p53. Cell Death Differ. 2006, 13:2140-2149.
39. Hu W., Zhang C., Wu R., Sun Y., Levine A., Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl. Acad. Sci. USA 2010, 107:7455-7460.
40. Suzuki S., Tanaka T., Poyurovsky M.V., Nagano H., Mayama T., Ohkubo S., Lokshin M., Hosokawa H., Nakayama T., Suzuki Y., Sugano S., Sato E., Nagao T., Yokote K., Tatsuno I., Prives C. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc. Natl. Acad. Sci. USA 2010, 107:7461-7466.
41. Jiang P., Du W., Mancuso A., Wellen K.E., Yang X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 2013, 493:689-693.
42. Mashima T., Seimiya H., Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Brit. J. Cancer 2009, 100:1369-1372.
43. Santos C.R., Schulze A. Lipid metabolism in cancer. FEBS J. 2012, 279:2610-2623.
44. Kuhajda F.P., Jenner K., Wood F.D., Hennigar R.A., Jacobs L.B., Dick J.D., Pasternack G.R. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl. Acad. Sci. USA 1994, 91:6379-6383.
45. Hatzivassiliou G., Zhao F., Bauer D.E., Andreadis C., Shaw A.N., Dhanak D., Hingorani S.R., Tuveson D.A., Thompson C.B. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005, 8:311-321.
46. Kuhajda F.P., Pizer E.S., Li J.N., Mani N.S., Frehywot G.L., Townsend C.A. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc. Natl. Acad. Sci. USA 2000, 97:3450-3454.
47. Goldstein I., Rotter V. Regulation of lipid metabolism by p53 - fighting two villains with one sword. Trends Endocrin. Metab.: TEM 2012, 23:567-575.
48. Zhu Y., Prives C. P53 and metabolism: the GAMT connection. Mol. Cell 2009, 36:351-352.
49. Assaily W., Rubinger D.A., Wheaton K., Lin Y., Ma W., Xuan W., Brown-Endres L., Tsuchihara K., Mak T.W., Benchimol S. ROS-mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress. Mol. Cell 2011, 44:491-501.
50. Yahagi N., Shimano H., Matsuzaka T., Najima Y., Sekiya M., Nakagawa Y., Ide T., Tomita S., Okazaki H., Tamura Y., Iizuka Y., Ohashi K., Gotoda T., Nagai R., Kimura S., Ishibashi S., Osuga J., Yamada N. P53 activation in adipocytes of obese mice. J. Biol. Chem. 2003, 278:25395-25400.
51. Soliman G.A. The integral role of mTOR in lipid metabolism. Cell Cycle 2011, 10:861-862.
52. Kimmelman A.C. The dynamic nature of autophagy in cancer. Gene. Dev. 2011, 25:1999-2010.
53. Crighton D., Wilkinson S., O'Prey J., Syed N., Smith P., Harrison P.R., Gasco M., Garrone O., Crook T., Ryan K.M. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006, 126:121-134.
54. Maiuri M.C., Galluzzi L., Morselli E., Kepp O., Malik S.A., Kroemer G. Autophagy regulation by p53. Curr. Opin. Cell Biol. 2010, 22:181-185.
55. Zhao Y.G., Zhao H., Miao L., Wang L., Sun F., Zhang H. The p53-induced gene Ei24 is an essential component of the basal autophagy pathway. J. Biol. Chem. 2012, 287:42053-42063.
56. Feng Z., Zhang H., Levine A.J., Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl. Acad. Sci. USA 2005, 102:8204-8209.
57. Tasdemir E., Maiuri M.C., Galluzzi L., Vitale I., Djavaheri-Mergny M., D'Amelio M., Criollo A., Morselli E., Zhu C., Harper F., Nannmark U., Samara C., Pinton P., Vicencio J.M., Carnuccio R., Moll U.M., Madeo F., Paterlini-Brechot P., Rizzuto R., Szabadkai G., Pierron G., Blomgren K., Tavernarakis N., Codogno P., Cecconi F., Kroemer G. Regulation of autophagy by cytoplasmic p53. Nat. Cell Biol. 2008, 10:676-687.
58. Morselli E., Tasdemir E., Maiuri M.C., Galluzzi L., Kepp O., Criollo A., Vicencio J.M., Soussi T., Kroemer G. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 2008, 7:3056-3061.
59. Deng C., Zhang P., Harper J.W., Elledge S.J., Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995, 82:675-684.
60. Michalak E.M., Villunger A., Adams J.M., Strasser A. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ. 2008, 15:1019-1029.
61. Brady C.A., Jiang D., Mello S.S., Johnson T.M., Jarvis L.A., Kozak M.M., Kenzelmann Broz D., Basak S., Park E.J., McLaughlin M.E., Karnezis A.N., Attardi L.D. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011, 145:571-583.
62. Valente L.J., Gray D.H., Michalak E.M., Pinon-Hofbauer J., Egle A., Scott C.L., Janic A., Strasser A. P53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep. 2013, 3:1339-1345.
63. Li T., Kon N., Jiang L., Tan M., Ludwig T., Zhao Y., Baer R., Gu W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012, 149:1269-1283.
64. Oren M., Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2010, 2:a001107.
65. Muller P.A., Vousden K.H. P53 mutations in cancer. Nat. Cell Biol. 2013, 15:2-8.
66. Freed-Pastor W.A., Prives C. Mutant p53: one name, many proteins. Genes. Dev. 2012, 26:1268-1286.
67. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., El-Naggar A.K., Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119:861-872.
68. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847-860.
69. Bougeard G., Sesboue R., Baert-Desurmont S., Vasseur S., Martin C., Tinat J., Brugieres L., Chompret A., de Paillerets B.B., Stoppa-Lyonnet D., Bonaiti-Pellie C., Frebourg T., French L.F.S.W. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J. Med. Genet. 2008, 45:535-538.
70. Freed-Pastor W.A., Mizuno H., Zhao X., Langerod A., Moon S.H., Rodriguez-Barrueco R., Barsotti A., Chicas A., Li W., Polotskaia A., Bissell M.J., Osborne T.F., Tian B., Lowe S.W., Silva J.M., Borresen-Dale A.L., Levine A.J., Bargonetti J., Prives C. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148:244-258.
71. Clendening J.W., Pandyra A., Boutros P.C., El Ghamrasni S., Khosravi F., Trentin G.A., Martirosyan A., Hakem A., Hakem R., Jurisica I., Penn L.Z. Dysregulation of the mevalonate pathway promotes transformation. Proc. Natl. Acad. Sci. USA 2010, 107:15051-15056.
72. Koyuturk M., Ersoz M., Altiok N. Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett. 2007, 250:220-228.
73. Zhang C., Liu J., Liang Y., Wu R., Zhao Y., Hong X., Lin M., Yu H., Liu L., Levine A.J., Hu W., Feng Z. Tumor-associated mutant p53 drives the warburg effect. Nat. Commun. 2013, 4:2935.
74. Goel A., Mathupala S.P., Pedersen P.L. Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. J. Biol. Chem. 2003, 278:15333-15340.
75. Chavez-Perez V.A., Strasberg-Rieber M., Rieber M. Metabolic utilization of exogenous pyruvate by mutant p53 (R175H) human melanoma cells promotes survival under glucose depletion. Cancer Biol. Therapy 2011, 12:647-656.